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Abstract: Open radical cystectomy is associated with a substantial rate of perioperative blood
transfusion. Early detection of potentially modifiable perioperative factors could reduce the need
for perioperative blood transfusion and thus positively impact the outcome. We conducted an
observational, single-center cohort study of 1168 patients undergoing cystectomy. Perioperative
blood transfusion was defined as the need for packed red blood cells and/or fresh frozen plasma
units within the first 24 h after the initiation of surgery. Multiple logistic regression analysis was
performed to model the association between risk factors and blood transfusion, and a nomogram
was developed. Blood transfusion occurred in 370/1168 patients (31.7%). Significant predictors were
age (OR: 1.678, (95% CI: 1.379–2.042); p < 0.001), blood loss ratio (6.572, (4.878–8.853); p < 0.001),
preoperative hemoglobin (0.316, (0.255–0.391); p < 0.001), tumor stage (2.067, (1.317–3.244); p = 0.002),
use of oral anticoagulants (2.70, (1.163–6.270), p = 0.021), and interaction between female sex and
blood loss ratio (1.344, (1.011–1.787); p = 0.042). Of the major predictors found to affect perioperative
blood transfusion, two can be influenced: blood loss ratio by meticulous surgery and hemoglobin
by preoperative optimization. Others such as age or advanced disease are not modifiable. This
emphasizes the importance of optimal management of patients prior to surgery.
Keywords: blood transfusion; predictors; cystectomy
1. Introduction
Radical cystectomy, pelvic lymph node dissection, and urinary diversion remain the
standard of care for patients with muscle-invasive bladder cancer [1]. Despite substantial
improvement over the last decades in terms of surgical technique including robotic-assisted
surgery, this procedure is still associated with substantial intraoperative blood loss and
transfusion of packed red blood cells (PRBC) with or without administration of fresh frozen
plasma (FFP) [2,3]. While robotic-assisted radical cystectomy has been associated with
reduced blood loss and blood transfusion and is gaining more relevance, open radical
cystectomy is still widely performed worldwide [4]. An overly restrictive blood transfusion
strategy has been shown to increase the risk of the composite event “inadequate oxygen
supply plus mortality” in a systematic review and meta-analysis, including context-specific
conditions like patients’ characteristics and clinical setting [5]. On the other hand, the re-
ported harm of blood transfusions is manifold. Perioperative blood transfusions have been
associated with worse outcomes following cystectomy [6–12]. Blood transfusions have an
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immunomodulatory and immunosuppressive effect in the perioperative period [13,14],
which predisposes patients to an increased rate of infection [15,16]. The intraoperative
period is also crucial as the physiological response to surgery can induce a pro-tumor envi-
ronment and thus negatively impact the control of minimal residual disease or metastatic
spread of tumor cells. In this setting, the administration of PRBC and FFP with its profound
negative effects on the immune system is detrimental [17]. In addition, blood transfusions
per se are associated with adverse reactions like transfusion-related acute lung injury,
which is considered the leading cause of blood transfusion-related morbidity. Finally, blood
transfusions result in a relevant increase in overall medical costs [18,19].
Cystectomy patients are particularly inclined to receive blood transfusions as a sub-
stantial number of patients (up to 50%) are anemic preoperatively [20,21]. Based on these
findings, we aimed to determine the risk factors for early blood transfusions, to identify po-
tentially modifiable pre- and intraoperative factors, and to develop a nomogram to identify
patients in need of preoperative optimization to reduce perioperative blood transfusions in
patients planned for cystectomy.
2. Materials and Methods
This study reports a single, tertiary, high case-load center cohort study in accordance
with the STROBE recommendations. Ethical approval was provided by the Ethics Com-
mittee of Canton Bern, Switzerland (2 June 2016, KEKBE 2016-00660), and the need for
informed consent was waived.
2.1. Study Population and Data Collection
We identified 1174 consecutive patients at the Department of Urology, Bern University
Hospital, between 4 January 2000 and 13 June 2016. We excluded six (0.51%) patients with
insufficient follow-up or incomplete data, leaving 1168 for the final analysis.
All patient data evaluated were from a prospectively maintained database, including
all relevant preoperative and oncological variables. Surgical factors were duration of
surgery, intraoperative blood loss, previous surgery, perioperative need for PRBC and
FFP transfusion, defined as blood transfusion within the first 24 h after the beginning of
surgery [22,23].
Our institution has performed a similar and standardized open surgical technique for
cystectomy and urinary diversion for the last 20 years, which has been described previously
according to the Studer’s technique [24,25]. All patients were followed prospectively.
During the observed period, PRBC was administered if hemoglobin values decreased to
<80 g/L (or <100 g/L in patients with coronary artery disease). FFP was administered in
the case of clinical coagulopathy or secondary to coagulation factor deficiency.
2.2. Outcome Measures
The need for a blood transfusion cannot be based on absolute blood loss alone but
also depends on the patient’s blood volume. We, therefore, decided to implement a blood
loss ratio based on the following calculations [26]:
Indexed blood volume: BVi = 70√
( BMI22 )
Estimated blood volume: BVe = BVi ∗ Weight
Blood loss ratio: BLr = BVeBLa
where BVi = indexed blood volume, BMI = body mass index, BVe = estimated blood volume,
BLr = blood loss ratio, BLa = absolute blood loss
2.3. Statistical Analysis
Baseline, intraoperative, and postoperative variables between patients who received
blood transfusions and patients who did not were compared. Continuous variables are
presented as median and interquartile ranges (IQR) and categorical variables as frequencies
(%). Group comparisons were calculated using the χ2 test for categorical and the Wilcoxon
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test for continuous variables. To identify independent risk factors for blood transfusions,
we performed multiple logistic regression analyses. We first partitioned data into a train-
ing (90%) and a testing set (10%) to avoid overfitting and to assess model performance
(ROC-AUC) on previously unseen data. We performed a stepwise selection procedure
minimizing the Akaike information criterion (AIC) using the MASS package for R for the
variable section. BMI, Charlson comorbidity index (CCI), use of blood thinners, previous
surgery, tumor stage (using polynomial contrasts), positive nodal stage and neoadjuvant
chemotherapy, duration of surgery, use of norepinephrine, and the total amount of fluid ad-
ministered as well as the presence of and all two-way interactions between blood loss ratio,
preoperative hemoglobin, age, and gender were evaluated for predictors of transfusion.
All continuous variables were normalized. Multicollinearity between predictors was
checked using the variance inflation factor. Marginal means were calculated for ordinal
categorical predictors using the “emmeans” package with multiplicity adjustment using
the multivariate t distribution method. Model fit was assessed with the le Cessie–van
Houwelingen–Copas–Hosmer global goodness of fit test, the Hosmer–Lemeshow test,
binned residual plots (“performance” package), and GiViTi calibration plots (“givitiR”
package) [27,28] (Appendix A, Table A1, Figures A1 and A2).
A nomogram was used to visualize the final logistic regression model using the “rms”
package [14]. We chose the inverse-logit transformation of the linear predictor to depict the
probabilities of the outcomes.
We conducted a sensitivity analysis using modern machine learning models, especially
elastic net logistic regression, random forest classification, and support vector machine.
The results are depicted in the Appendices B and C (Table A3 and Figure A3).
A two-sided p < 0.05 was considered significant. Analyses were performed using
the R software environment (R Foundation for Statistical Computing, Vienna, Austria,
Version 4.0.2).
The sample size was based on a consecutive series of patients who underwent cys-
tectomy and urinary diversion during the observation time. No formal statistical power
calculation was calculated before the study.
3. Results
Overall, 370/1168 patients (31.7%) received blood transfusions within 24 h after
the beginning of surgery. In the univariate analysis, patients in the transfused group
were older (71 (64–77) vs. 67 years (59–74); p < 0.001), more often had neoadjuvant
chemotherapy (20.3% vs. 12.7%; p = 0.001), were more often taking oral anticoagulants
(5.7% vs. 2.9%; p = 0.03), had lower preoperative hemoglobin values (120 (104–131) vs.
135 g/L (123–145), p < 0.001) and were more comorbid (p < 0.001). There was a higher
proportion of women (37.8% vs. 29.9%, p = 0.009) and more with advanced disease (positive
nodal stage (p = 0.009) and tumor stage (p < 0.001)) in the transfused group. Duration of
surgery was longer in transfused patients (409 (351–454) vs. 390 min (345–426); p < 0.001),
and blood loss was higher (1400 mL (1000–2088) vs. 900 mL (700–1245); p < 0.001). This last
observation persisted when blood loss ratio was applied (0.31 (0.22–0.42) vs. 0.19 (0.14–0.26).
Consequently, the amount of crystalloids administered was higher 5.3 mL/kg/h (3.80–7.06)
vs. 4.5 mL/kg/h (3.30–6.02); p < 0.001) in transfused patients (Table 1).
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Table 1. Baseline, oncological, and surgical/anesthetic characteristics.
Non-Transfused Blood Transfusion p-Value SMD
Baseline Characteristics
Number of Patients (%) 798 (68.3) 370 (31.7)
Age (years) (median (IQR)) 67.08 (59.21, 74.29) 71.05 (64.04, 77.41) <0.001 0.296
Sex (female) (%) 239 (29.9) 140 (37.8) 0.009 0.167
BMI (kg/m2) (median (IQR)) 25.56 (22.86, 28.72) 25.40 (22.73, 28.51) 0.710 0.039
Charlson Comorbidity Index (%) <0.001 0.317
0 304 (38.1) 106 (28.6)
1 131 (16.4) 48 (13.0)
2 181 (22.7) 90 (24.3)
3 98 (12.3) 56 (15.1)
4 55 (6.9) 37 (10.0)
5 and more 29 (3.6) 33 (8.9)
Oral anticoagulation (%) 23 (2.9) 21 (5.7) 0.030 0.138
Thrombocyte aggregation inhibition (%) 87 (10.9) 40 (10.8) 1.000 0.003
Preoperative Hb (g/L) (median (IQR)) 135.00 (123, 145) 120.00 (104, 130.75) <0.001 0.826
Preoperative Tc (G/L) (median (IQR)) 251.5 (211, 309) 267.00 (214.25, 338.75) 0.002 0.236
Oncological characteristics
Confirmed tumor stage pT (%) <0.001 0.414
0 201 (25.2) 59 (15.9)
1 111 (13.9) 38 (10.3)
2 193 (24.2) 75 (20.3)
3 233 (29.2) 129 (34.9)
4 60 (7.5) 69 (18.6)
Confirmed positive nodal stage (%) 167 (20.9) 104 (28.1) 0.009 0.168
Neoadjuvant chemotherapy (%) 101 (12.7) 75 (20.3) 0.001 0.206
Surgical/anesthetic characteristics
Previous surgery (%) 326 (40.9) 162 (43.8) 0.378 0.059
Duration of surgery (min)
(median (IQR)) 390 (345, 425.75) 408.50 (351, 454) <0.001 0.293
Blood loss (ml) (median (IQR)) 900 (700, 1245) 1400.00 (1000, 2087.5) <0.001 0.782
Blood loss ratio (median (IQR)) 0.19 (0.14, 0.26) 0.31 (0.22, 0.42) <0.001 0.862
Norepinephrine use (%) 519 (65.0) 203 (54.9) 0.001 0.209
Crystalloids (ml/kg/h) (median (IQR)) 4.5 (3.30, 6.02) 5.30 (3.80, 7.06) <0.001 0.253
Abbreviations: Tc, thrombocytes; Hb, hemoglobin, SMD: standardized mean difference.
The multiple logistic regression model is shown in Figure 1. ROC-AUC assessed on an
independent test set was 0.87. The model showed a well-calibrated goodness of fit (Hosmer
and Lemeshow C test: p = 0.617, Hosmer and Lemeshow H test: p = 0.100 and le Cessie–van
Houwelingen–Copas–Hosmer test: p = 0.525). Diagnostic performance indicators were
65% sensitivity and 91% specificity. Multiple logistic regression detected blood loss ra-
tio (OR: 6.572 (95% CI: 4.878–8.853); p < 0.001), oral anticoagulants (2.701 (1.163–6.270),
p = 0.021), preoperative hemoglobin (0.316 (0.255–0.391), p < 0.001), age (1.678 (1.379–2.042),
p < 0.001), and tumor stage (linear trend: 2.067 (1.317–3.244), p = 0.002 and quadratic trend:
1.623 (1.059–2.489), p = 0.026) as significant predictors for blood transfusions (Table 2).
The interaction between female sex and blood loss ratio was significant (1.344 (1.011–1.787),
p = 0.042). Table 3 shows the estimated marginal means for confirmed tumor stage with
implemented polynomial contrasts. With more advanced tumor stages, there was a sig-
nificantly increased risk for blood transfusions: pT3-4 vs. pT0-2 (OR: 2.028 (95% CI:
1.251–3.287), p = 0.001).
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Figure 1. Effect plots for the predictors included in the final model (multiple logistic regression with adjusted odds ratio).
Asterisks show the level of significance, *** for p < 0.001, ** for p < 0.01, * f r p < 0.05.
Table 2. Multivariate analysis of factors associated with the rate of early blood transfusion.
Variables OddsRatio 95% CI p-Value
* Blood loss ratio 6.5717 4.8781–8.8532 <0.0001
* Oral anticoagulants 2.7007 1.1633–6.2699 0.0208
* Preoperative Hemogl i ( / ) 0.31 0.2545–0.391 < .0001
* Age (y) 1.6782 1.3794–2.0416 <0.0001
* Confirmed tumor stage (linear trend) 2.0670 1.317–3.2441 0.0016
* Confirmed tumor stage (quadratic trend) 1.6233 1.0587–2.4892 0.0263
* Confirmed tu or stage (cubic trend) 0.9408 0.6111–1.4484 0.7818
* Confirmed tumor stage (quartic trend) 0.9705 0.6541–1.4398 0.8816
* Duration of surgery < (min) 1.2011 0.9812–1.4701 0.0757
* Norepinephrine used 0.7220 0.5028–1.0367 0.0776
Sex (female) 1.0356 0.8666–1.2376 0.7002
Blood loss ratio * preoperative Hb 1.2619 0.9714–1.6393 0.0814
* Blood loss ratio * female gender 1.3443 1.0 12–1.787 .0417
* = Variables included in the fi al model. Level of significance p < 0.05, CI = confidence interval, Hb = hemoglobin.
Figure 2 shows the nomogram for predicting blood transfusions, based on the final
multiple logistic regression model. Exemplary patients are presented in Appendix D
(Figures A4–A8) and Appendix E (Tables A4–A9).
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Table 3. Estimated marginal means for tumor stage (i.e., mean change contrasts for confirmed
tumor stage).
Variable Contrast Odds Ratio 95% CI p-Value
Confirmed tumor stage 0 vs. 1–4 1.2595 0721–2.199 0.6774
Confirmed tumor stage 0–1 vs. 2–4 1.6052 0.978–2.635 0.0662
Confirmed tumor stage 0-2 vs. 3–4 2.0278 1.252–3.285 0.0014
Confirmed tumor stage 0–3 vs. 4 2.3849 1.223–4.650 0.0057
Level of significance p < 0.05, CI = confidence interval.
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Figure 2. Nomogram of the logistic regression model to predict early perioperative blood transfusion.
The sensitivity analyses using sophisticated machine learning models showed a non-
inferiority of our traditional logistic regression model. We thus favored it because of the
better interpretability (Appendices B and C).
4. Discussion
This study aimed to detect predictors for perioperative blood transfusion and to
develop a nomogram to pre ict the need for transfusion in patients undergoing cystectomy.
In our cohort, we found an incidence of blood transfusion of around 30%, comparable with
the current literature [29,30].
Blood loss ratio, preoperative hemoglobin, and advanced age had the strongest associ-
ation with the likelihood of receiving a blood transfusion. Other relevant factors were the
use of oral anticoagulants, advanced tumor stage, and interaction of female sex with blood
loss ratio.
Age and tumor stage are given for the perioperative period, but their impact on the
probability of a blood transfusion is limited as they contribute to the total score in the
nomogram by less than 2 points. This holds true for the use of oral anticoagulants as well.
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However, we identified two potentially modifiable factors that highly influence the
probability of blood transfusion. These are easily discernable in the developed nomogram
by a thick line indicating their predominance: preoperative hemoglobin and blood loss
ratio outweigh all other factors by far, as they contribute up to 16 points to the total score
in the nomogram.
The leading and most evident protective factor is a high circulating oxygen transport
capacity, thus a high preoperative hemoglobin value. Its higher impact compared to other
factors like duration of surgery, tumor stage, or oral anticoagulation is striking, particu-
larly for female patients. This further emphasizes the importance of a solid preparation
of patients by implementing standardized patient blood management concepts prior to
cystectomy. Preoperative anemia should be corrected accordingly, through intravenous
administration of an iron formulation, which results in a more rapid response compared to
the oral formulation [31,32]. In addition, vitamin B12 and folic acid are also recommended
for intravenous iron administration [33].
Furthermore, the use of continuous low-dose norepinephrine intraoperatively was
included in the final model and nomogram, albeit not reaching statistical significance.
This has been shown previously and is now confirmed in a large series of more than
1000 patients [34,35]. The protective effect of norepinephrine against blood transfusion is
most likely attributed to vasoconstriction induced by the pre-emptive/concomitant use of a
predominantly α-adrenergic vasopressor with only mild but dose-dependent β-adrenergic
effects [29,35].
Female sex has been associated with an increased rate of blood transfusion in cardiac
and major non-cardiac surgery [36–38]. Furthermore, Siegrist et al. found in a large
cystectomy cohort that blood loss and transfusion rate were higher in 280 females [39].
In our series, this is only true if interacted with the blood loss ratio, potentially due to
the lower circulating blood volume in females. Based on our nomogram, anemic female
patients have a nearly twofold higher risk of receiving a blood transfusion than male
patients with a similar blood loss ratio. In addition, we confirmed once again that the type
of urinary diversion has no impact on blood loss and the rate of blood transfusion [34].
Although blood transfusions can be lifesaving and necessary in some cases, and they
are safer than they have ever been, they still negatively influence the immune system.
Blood transfusions are associated with promoting a proangiogenic environment inducing
tumor growth by releasing cytokines IL6, IL10, and TNFα, and regulatory T-cell activation
suppressing the anti-tumoral Th1 response [14]. Notably, not only PRBC but also FFP
induce a pro-inflammatory burden and have the potential to affect natural killer cell activity.
FFP contains Th2 cytokines, which induce a dose-dependent release of TNFα and IL10 [40].
This cytokine response is known to be pro-tumoral.
The ideal perioperative blood transfusion strategy in major oncological surgery re-
mains unclear. This is especially important for older comorbid patients because a too
restrictive blood transfusion regimen could increase the risk of early major postoperative
complications (ischemic, cardiogenic). On the other hand, a too liberal strategy raises the
risk of thromboembolic events [5,41–43]. Thus, a careful balance between the short-term
benefits of blood transfusions in terms of reduction in early major postoperative complica-
tions versus the long-term benefits in terms of better cancer-related outcomes should be
made depending on the patient's characteristics. Meticulous surgical technique reducing
blood loss, restrictive fluid administration avoiding hemodilution, normothermia reducing
the risk of coagulopathy, and a restrictive threshold for transfusions of PRBC and FFP
are valuable intraoperative options to reduce blood transfusion rates [29,44]. In the era of
cryoprecipitate and fibrinogen concentrates, the indication for FFP should be reconsidered
as it has been associated with transfusion-associated circulatory overload and transfusion-
related acute lung injury. Malignancy and the disturbances in the perioperative period are
known to induce prothrombotic stimuli, and administration of blood transfusions has been
associated with an elevated risk of thromboembolic events [45]. Hence, the administration
of PRBC and FFP units must be evaluated carefully.
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The key finding of this study is that the most important and most efficient method to
avoid blood transfusion is preoperative patient optimization as depicted in our nomogram.
The cornerstone in preparing patients scheduled for cystectomy is to optimize hemoglobin
levels in anemic patients to within the normal to high hemoglobin range (≥130 g/L in both
sexes) as proposed in the international consensus statement on the perioperative manage-
ment of anemia and iron deficiency [46]. Their recommendations include a perioperative
care pathway to investigate and correct anemia. In order to minimize the risk of unfa-
vorable transfusion-related outcomes, the implementation of patient blood management
strategies is valuable, even if the time between decision and surgery is limited, to avoid
postponing major cancer-related surgery [47].
5. Conclusions
The incidence of perioperative blood transfusions in patients undergoing cystectomy
was around 30%. Of the predictors affecting blood transfusions, only blood loss ratio and
preoperative hemoglobin can be addressed by meticulous surgery and surgical technique,
or optimization of preoperative hemoglobin as depicted in our nomogram. Others, like age
or advanced tumor disease, are not modifiable. This emphasizes the importance of optimal
preparation of patients undergoing cystectomy and minimal bleeding during surgery. We,
therefore, strongly suggest the implementation of solid patient blood management, as
previously proposed, to increase preoperative hemoglobin concentration.
Limitations
This is a retrospective study based on prospectively recorded data. We, therefore,
cannot exclude deviation of the transfusion protocol due to clinical decision-making. This
limits the generalizability of these findings. However, we were able to confirm, in part,
precedent results. In addition, there is a high likelihood for a negative selection bias in the
group receiving blood transfusions. Patients receiving blood transfusions were more likely
to have more advanced oncological disease, were older, and more comorbid at the time of
surgery. A randomized, controlled trial, which would be the ideal design to avoid bias and
answer this question, seems ethically not justifiable.
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Appendix A
Table A1. Model diagnostics variance inflation factor (VIF) >10 indicating the presence
of multicollinearity.
Variable VIF Df
Blood loss ratio 1.468 1
Oral anticoagulants 1.041 1
Preoperative hemoglobin 1.322 1
Age 1.180 1
Tumor stage 1.155 4
Duration of surgery 1.326 1
Norepinephrine 1.071 1
Female sex 1.091 1
Blood loss ratio x preoperative hemoglobin 1.109 1
Blood loss ratio x female 1.138 1
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Appendix B. Comparison with Machine Learning Models
All machine learning models were performed using the “tidymodels” package for R.
Elastic Net Logistic Regression
A 10-fold repeated 10-fold cross-validation was performed to find the best tuning
parameters out of 50 combinations, which were chosen by the maximum entropy method.
The best model was selected with a penalty of 0.0331 and a mixture parameter of 0.381
(0 being only ridge regression and 1 being only lasso regression), axi izing ROC-AUC.
Random Forest
A 10-fold repeated, 10-fold cross-validation was performed to find the best tuning
parameters out of 100 combinations, which were chosen by the maximum entropy method.
The best model was selected with mtry (number of variables available for splitting at each
tree node) o 3 and a min_n (minimum number of data points in a node that are requir d for
the nod to be split urther) f 34, maximizing ROC-AUC. The umber of trees contained
in the ensemble was always 1000.
Support Vecto Machine
We used a radial basis function for the kernel. A 10-fold repeated, 10-fold cross-
validation was performed to find the best tuning parameters out of 100 combinations,
which were chosen by the maximum entropy method. The best model was selected with a
cost of 3 and a sigm for the kernel of 0.0339, maximizing ROC-AUC.
Model P rform nce
Model performance was assessed using a separate test set comprised of 10% of the
whol data set as described in the Methods s cti n of the main article.
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Table A2. Comparison.
Model Accuracy ROC-AUC Brier
Elastic Net Logistic Regression 0.783 0.867 0.137
Stepwise Logistic Regression 0.800 0.864 0.136
Support Vector Machine 0.800 0.864 0.133
Random Forest 0.800 0.829 0.147
Appendix C. Feature Importance
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Table A6. Preoperative hemoglobin—Blood loss ratio—Sex. 
 BLOOD LOSS RATIO—MALE BLOOD LOSS RATIO—FEMALE 
HB 0.1 0.2 0.3 0.4 0.1 0.2 0.3 0.4 
160 1 3 5 8 0 3 6 9 
150 2 4 6 8 1 4 7 10 
140 3 5 7 9 3 5 8 10 
130 5 6 8 10 4 6 9 11 
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Table A5. Preoperative hemoglobin—Blood loss ratio—Sex.
BLOOD LOSS RATIO—MALE BLOOD LOSS RATIO—FEMALE
HB 0.1 0.2 0.3 0.4 0.1 0.2 0.3 0.4
160 1 3 5 8 0 3 6 9
150 2 4 6 8 1 4 7 10
140 3 5 7 9 3 5 8 10
130 5 6 8 10 4 6 9 11
120 6 8 9 11 5 7 10 12
110 7 9 10 12 6 8 11 13
100 8 10 11 13 8 10 12 14
90 10 11 12 13 9 11 13 14
80 11 12 13 14 10 12 13 15
70 12 13 14 15 11 13 14 16















Table A9. Probability of transfusion.
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